Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Other Non Operating Income of -$75000.0 for Q1 2026, up 77.61% year-over-year from -$42226.9 in Q1 2025, and down 107.06% quarter-over-quarter from $1.1 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$75000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 77.61% year-over-year to -$75000.0; the TTM figure through Mar 2026 stood at $261000.0 (up 132.54% YoY), while the FY2024 annual figure was -$1.2 million, down 83.94% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$75000.0, down from $1.1 million in the prior quarter.
- The five-year high for Other Non Operating Income was $1.1 million in Q4 2025, with the low at -$747000.0 in Q1 2024.
- The 5-year median for Other Non Operating Income is -$141000.0 (2024), against an average of -$147000.0.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income slumped 1278.95% in 2023, then jumped 576.43% in 2025.
- Amylyx Pharmaceuticals' Other Non Operating Income stood at -$689000.0 in 2022, then soared by 124.82% to $171000.0 in 2023, then declined by 8.19% to $157000.0 in 2024, then surged by 576.43% to $1.1 million in 2025, then slumped by 107.06% to -$75000.0 in 2026.
- Business Quant data shows AMLX's Other Non Operating Income at -$75000.0 in Q1 2026, $1.1 million in Q4 2025, and -$180000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53,000.00 |
| Mar 31, 2026 | -75,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | -180,000.00 |
| Jun 30, 2025 | -546,000.00 |
| Mar 31, 2025 | -335,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | -141,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Mar 31, 2024 | -747,000.00 |
| Dec 31, 2023 | 171,000.00 |
| Sep 30, 2023 | -488,000.00 |
| Jun 30, 2023 | -81,000.00 |
| Mar 31, 2023 | -262,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | 199,000.00 |
| Jun 30, 2022 | -42,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -59,000.00 |
| Sep 30, 2021 | -227,000.00 |